OncoLink Cancer Treatment and Resources
OncoLink Cancer Treatment and Resources
Link to OncoLink

Primary Chemotherapy (PCT) For Patients With Operable Oral Cavity Cancer: Results Of A Randomized Study

Diana Stripp, MD

University of Pennsylvania Cancer
Ultima Vez Modificado: 13 de mayo del 2001

Presenter: Lisa Licitra
Affiliation: Istituto Nazionale Tumori, Milan, Italy

Background:

    This study was designed to investigate the impact of neoadjuvant chemotherapy on primary surgery in operable oral cavity cancer.

Materials and Methods:

  1. Randomized trial of 195 patients with operable squamous cell carcinoma of the oral cavity comparing pCT followed by surgery ± RT (arm A) with surgery ± RT (arm B).
  2. Chemotherapy consisted of Cisplatin 100 mg/m2 day 1 and 5-Fluorouracil 1000 mg/m2 day 1-5 for 3 cycles.
  3. RT was performed in case of positive surgical margins, soft tissue invasion, more than 3 pathological nodes and/or extracapsular spread.

Results:

  1. Distribution by stage was similar in each group
  2. Chemotherapy was stopped for toxicity (12 pts), no response (11 pts), refusal (3 pts), protocol violation (1 pt). Three toxic deaths occurred in arm A, due to: cardiotoxicity (2 pts), sepsis (1 pt). Surgical morbidity was similar in both arms.
  3. Histologically positive surgical margins were found in 4% of pts in arm A and 12% in arm B.
  4. Eighty-two pts were evaluable for pathological response to pCT. Complete pathological response (pCR) was observed in 27% of pts and small foci of residual tumor (near pCR) were detected in 18%.
  5. Postoperative radiotherapy was performed in arm A 33% and arm B 46% of pts.
  6. The 5-yr survival was arm A 54% (95% C.I: 44- 65 %) and arm B 55% (95% C.I: 44-65 %). DFS was similar in both arms. Patients in near pCR or pCR had a 5 yr DFS of 88% comparing to 58% of cases not achieving it.
  7. Transmandibular surgery was performed in 44% of arm A and 62% of arm B pts.

Authors' Conclusions

  1. Primary chemotherapy did not improve survival of surgery ± RT in operable oral cavity cancer.
  2. The improved DFS of patients with major pathological response may be due to chemotherapy activity and/or to its selecting ability of good prognosis tumors.
  3. Chemotherapy appeared to allow less aggressive surgery to be performed on patients

Clinical/Scientific Implications:

    A less aggressive surgical procedure may allow organ preservation and improve cosmetic outcomes. However, further studies will be needed to evaluate the impact of neoadjuvant chemotherapy to primary surgery or to definitive radiation.

ASCO Abstract 890

Saturday | Sunday | Monday | Tuesday

OncoLink ASCO 2001 coverage is provided by an unrestricted educational grant from Amgen

OncoLink I wish u knew...

Marianna provides tips for people starting cancer treatments and talks about the cancer experience. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS